BioCentury on BioBusiness,
DuPont eschews a spin-out
Monday, March 15, 1999
DuPont eschews a spin-out
By Kathryn Calkins
DuPont's plans to create a tracking stock for its life sciences businesses is in line with moves the company began last year to hive off the group from its slower-growing chemicals and other businesses. But skeptics may question whether DuPont is moving too late to create a competitive life sciences play, and whether last week's tracking stock announcement simply sets the stage for an acquisition by its much larger competitors - or for a complete uncoupling of life sciences from the rest of the company.
Last May, as part of a new life sciences focus for the company, DuPont decided to consolidate its three life science-related businesses - agricultural enterprises, pharmaceuticals and central R&D - into one group. At the time, the company said its goal would be to obtain 30 percent of its earnings from life sciences within three years (see BioCentury, May 18, 1998
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]